8158 — China Regenerative Medicine International Cashflow Statement
0.000.00%
Last trade - 00:00- HK$121.70m
- HK$152.69m
- HK$90.62m
- 22
- 59
- 42
- 34
Annual cashflow statement for China Regenerative Medicine International, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -142 | 64.3 | 8.27 | -108 | — |
| Depreciation | |||||
| Non-Cash Items | -137 | -41.2 | 8.06 | 84 | — |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -122 | -26.2 | -34.1 | 18.8 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -399 | -3.02 | -17.7 | 6.34 | — |
| Capital Expenditures | 0 | -0.809 | -2.59 | -0.274 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 327 | 10.1 | 0.001 | 0.012 | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 327 | 9.27 | -2.59 | -0.262 | — |
| Financing Cash Flow Items | 29.7 | -0.174 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 67.4 | -1.39 | 7.32 | -7.36 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.52 | 5.16 | -8.08 | 1.49 | — |